<DOC>
	<DOCNO>NCT01842165</DOCNO>
	<brief_summary>The purpose study determine 68Gallium-octreotate 18Fluorodesoxyglucose uptake , apparent diffusion coefficient post 177Lu-octreotate SPECT/CT dosimetry reliable predictor lesion-by-lesion treatment outcome .</brief_summary>
	<brief_title>177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging Refractory NETs</brief_title>
	<detailed_description>This feasibility study evaluate use 177Lutetium-octreotate treatment advance refractory Neuroendocrine Tumors . Objectives study : 1 . Primary ( lesion basis ) : To assess value follow parameter ( obtain functional molecular imaging ) predict lesion-by-lesion PRRT treatment outcome : - 18FDG uptake 18FDG PET/CT - 68Ga-octreotate uptake 68Ga-octreotate PET/CT - Apparent diffusion coefficient diffusion weight MRI ( 3 parameter , absolute value baseline ) - Tumor dosimetry post 177Lu-octreotate SPECT/CT cycle . 2 . Secondary ( patient basis ) : To generate patient-based response model base previously define parameter . 3 . Exploratory ( lesion basis ) : To assess value parameter mention primary objective predict lesion-by-lesion PRRT treatment outcome : - absolute value three image parameter relative change cycle ; - serial tumor dosimetry post-177Lu-octreotate SPECT/CT cycle . Treatment consist 177Lu-octreotate injection fix activity 7,4 GigaBecqurel , give 11-13 week apart , inject intravenously simultaneous infusion amino acid solution . ( Before amino acid nephroprotection , ondansetron , methylprednisolone metoclopramid , give intravenously order prevent nausea vomit ) . Approximately 30 min begin amino acid solution , 177Lu-octreotate co-infused 15-30 minute . The amino acid infusion continue rate 3-5 hour ( total infusion last 4-6 hour ) . In total , 4 cycle ( = injection 177Lu-octreotate ) plan . However , total number administer cycle limit critical organ ( kidneys bone marrow ) threshold toxicity . Treatment efficacy assess : - lesion-basis ( change long transversal diameter ) . - patient-basis use Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Patientbased : 1 . Age equal 18 year . 2 . Histologyproven advance GEPNETs . 3 . Disease progression define follow ( least one follow ) : Radiological disease progression ( accord RECIST 1.1 ) MRI CT last 12 month Or Disease progression somatostatin receptorimaging , PET/CT SPECT/CT last 12 month [ apparition new lesion ( ) increase transaxial plane diameter 30 % image modality ] Or Both follow criterion ( a+b ) : 1. clinical progression : sustain ( 2 week ) increase NETspecific hormonal hypersecretion relate symptom frequency 50 % , sustain ( 2 week ) increase severity 1 grade ( accord NCICTCAE version 4.03 ) . 2. biochemical progression : increase NETspecific tumor marker ( plasma Chromogranin A , plasma NSE , urine 5HIAA ) two successive measurement . 4 . Disease refractory SSA 's and/or standard systemic therapy available Belgium time inclusion criterion . 5 . Longacting SSAs discontinue least 4 week study treatment start date , need , switch shortacting analogue stop 48h treatment date . 6 . Adequate renal function GFR ≥ 50 mL/min/1.73m2 ( evaluated 51CrEDTA test ) . 7 . Adequate bone marrow function hemoglobin ≥ 9 g/dL ; neutrophil ≥ 1.5·103/μL ; platelet count ≥ 100·103/μL . 8 . Adequate liver function total bilirubin ≤ 2 x ULN transaminases ≤ 5 x ULN , serum albumin &gt; 3 g/dL normal prothrombin time ( &gt; 70 % ) . 9 . ECOG Performance Status ≤ 1 . 10 . Women childbearing potential men partner childbearing potential must agree use highly‐effective form contraception duration study participation six month end treatment . A pregnancy test ( serum ) must perform within 4 week prior inclusion every female patient childbearing potential must negative . 11 . Patient 's write informed consent obtain prior study procedure . 12 . All necessary baseline procedure perform within 4 week prior first 177Luoctreotate injection ( D0 ) . Lesionbased : 13 . The patient must least one target lesion fulfil criterion : On 68Gaoctreotate PET/CT : tumor uptake high physiological liver uptake ( grade III IV Rotterdam visual score ) lesion long transaxial plane diameter ≥20mm ( measure CT , part PET/CT ) ; At least one lesion morphologically measurable accord RECIST 1.1 progressive MRI ( CT MRI applicable ) ; Target lesion previously irradiate . 1 . Resectable tumor curative intent . 2 . Any major surgery within last 6 week prior inclusion study 3 . Radiotherapy , chemotherapy , embolization , mammalian target rapamycin ( mTOR ) inhibitor , receptor tyrosinekinase inhibitor , interferon , investigational therapy within last 12 week prior inclusion study . 4 . Diffuse bone marrow infiltration baseline 68Gaoctreotate PET/CT confirm MRI . 5 . Prior external beam radiotherapy kidneys 25 % bone marrow . 6 . Patients know uncontrolled brain metastasis . 7 . Patients significant medical , neuropsychiatric , surgical condition , currently uncontrolled treatment , , investigator 's opinion , may interfere completion study . 8 . Pregnant lactating patient . 9 . Women childbearing potential men partner childbearing potential refusing adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Peptide Receptor Radionuclide Therapy ( PRRT )</keyword>
	<keyword>Neuroendocrine Tumors</keyword>
</DOC>